
Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia
June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di
Updated on: October 24,2023
27

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia
June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di
Updated on:October 24,2023
27
